secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001140361-24-044703
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed Q3 ARIKAYCE revenue $93.4M (+18% YoY); net loss $1.27/sh; adds $150M loan
--------------------------------------------------------------------------------

- ARIKAYCE global revenue $93.4M in Q3 2024, up 18% YoY; US $66.9M, Japan $21.0M, Europe/RoW $5.6M.
- Net loss $220.5M ($1.27/sh) vs $158.9M ($1.11/sh) in Q3 2023; operating loss $213.4M.
- NDA for brensocatib in bronchiectasis on track for Q4 2024; potential US launch mid-2025.
- Amended Pharmakon loan adds $150M tranche at 9.60% fixed, maturity extends to Sept 2029.
- Ended Q3 with ~$1.5B cash; redeemed $225M convertible notes; raised $371M net via ATM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036124044703/0001140361-24-044703-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036124044703/ef20037942_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-044703

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer